Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study ; volume:20 ; number:1 ; day:30 ; month:10 ; year:2018 ; pages:1-10 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (30.10.2018), 1-10, 12.2018
- Creator
-
Roughley, Matthew
Sultan, Alyshah Abdul
Clarson, Lorna
Muller, Sara
Whittle, Rebecca
Belcher, John
Mallen, Christian D.
Roddy, Edward
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1746-1
- URN
-
urn:nbn:de:101:1-2018121822375554168834
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Roughley, Matthew
- Sultan, Alyshah Abdul
- Clarson, Lorna
- Muller, Sara
- Whittle, Rebecca
- Belcher, John
- Mallen, Christian D.
- Roddy, Edward
- SpringerLink (Online service)
Other Objects (12)
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age